We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PLS:ASXPLS Group Limited Analysis

Data as of 2026-06-17 - not real-time

A$6.36

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Technical outlook: The stock is riding a bullish trend with short‑term moving averages stacked above longer‑term averages and price comfortably above the identified support level. Momentum indicators are mixed – RSI sits in the mid‑50s indicating neutral pressure, while the MACD histogram has turned negative and the signal line suggests a bearish bias. Volume has been on a downtrend, and 30‑day volatility remains elevated, though beta is below one, pointing to lower systematic risk.
Valuation & fundamentals: Current pricing is well above the discounted cash‑flow estimate and the price‑to‑book multiple is high, while the forward price‑earnings ratio hovers around the low‑20s despite trailing earnings being negative. The company carries a sizable debt load and does not pay a dividend, yet it has posted robust revenue growth driven by lithium projects and a strong forward earnings outlook.
Market sentiment: Recent headlines highlight that PLS has outperformed many peers in the ASX 200, with notable share price gains over the past year, but the combination of overvaluation and mixed short‑term technical signals suggests caution before adding more exposure.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • price approaching resistance with bearish MACD
  • declining volume trend
  • high short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • strong revenue growth and positive forward earnings
  • still significantly above fair value
  • high debt relative to equity

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • structural demand growth for lithium
  • potential margin improvement as projects scale
  • solid cash position despite debt

Key Metrics & Analysis

Financial Health

Revenue Growth46.60%
Profit Margin-9.67%
P/E Ratio22.3
ROE-2.77%
ROA0.09%
Debt/Equity20.17
P/B Ratio5.7
Op. Cash FlowA$285.5M
Free Cash FlowA$-93887376

Technical Analysis

TrendBullish
RSI54.1
SupportA$5.52
ResistanceA$6.81
MA 20A$6.26
MA 50A$6.06
MA 200A$4.38
MACDBearish
VolumeDecreasing
Fear & Greed Index92.3

Valuation

Fair ValueA$2.31
Target PriceA$5.70
Upside/Downside-10.42%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.88
Volatility50.26%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.